Zhang, Lu http://orcid.org/0000-0002-7492-6047
Jing, Di
Jiang, Nian
Rojalin, Tatu
Baehr, Christopher M.
Zhang, Dalin
Xiao, Wenwu
Wu, Yi
Cong, Zhaoqing
Li, Jian Jian http://orcid.org/0000-0003-3694-9675
Li, Yuanpei http://orcid.org/0000-0002-4015-646X
Wang, Lei http://orcid.org/0000-0003-1405-9815
Lam, Kit S. http://orcid.org/0000-0002-3076-6969
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA115483, R01CA115483, R01CA115483, R01CA115483, R01CA115483, R01CA115483, R01CA115483, R01CA115483, R01CA115483, R01CA115483, R01CA115483, R01CA199668, U01CA198880, U01CA198880)
U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (R01EB012569, R01EB012569)
National Natural Science Foundation of China (51573101)
Article History
Received: 11 February 2019
Accepted: 27 November 2019
First Online: 27 January 2020
Competing interests
: The authors declare the following competing interests. K.S.L., L.Z., D.J. and L.W. are co-inventors of a pending patent on fibrillar-transformable nanoparticles. K.S.L. is the founding scientist of LamnoTherapeutics Inc., which plans to develop the nanotherapeutics described in the manuscript. The remaining authors declare no competing interests.